Earnings summaries and quarterly performance for Enliven Therapeutics.
Executive leadership at Enliven Therapeutics.
Board of directors at Enliven Therapeutics.
Research analysts covering Enliven Therapeutics.
Recent press releases and 8-K filings for ELVN.
Enliven Therapeutics Appoints New CEO and Restructures Leadership
ELVN
CEO Change
Management Change
Executive Compensation
- Enliven Therapeutics (ELVN) appointed Rick Fair as its new Chief Executive Officer and a member of the Board of Directors, effective December 11, 2025.
- Sam Kintz, Co-Founder and former CEO, transitioned to the role of Head of Pipeline.
- Mr. Fair, with over 25 years of experience in product development and commercialization, will lead the company's next phase, including a pivotal Phase 3 trial for ELVN-001 in 2026.
- Fair's compensation package includes an annual base salary of $660,000, a target annual bonus of 55% of his base salary, and a stock option award to purchase 875,000 shares.
Dec 11, 2025, 2:11 PM
Enliven Therapeutics Announces New CEO
ELVN
CEO Change
Management Change
New Projects/Investments
- Rick Fair has been appointed as the new Chief Executive Officer and a member of the Board of Directors of Enliven Therapeutics, effective December 11, 2025.
- Sam Kintz, Co-Founder and former CEO, will transition to a new role as Head of Pipeline.
- This leadership change is intended to support the company's next phase, including the initiation of a pivotal Phase 3 trial for ELVN-001 in chronic myeloid leukemia (CML) patients in 2026 and its commercialization.
- Mr. Fair brings over 25 years of experience in product development and commercialization, having previously served as President and CEO of Bellicum Pharmaceuticals and in commercial leadership roles at Roche/Genentech.
Dec 11, 2025, 2:00 PM
EnLiven Therapeutics Updates on 001 Clinical Development and Financial Position
ELVN
New Projects/Investments
Guidance Update
- EnLiven Therapeutics (ELVN) is developing 001, an ATP-competitive, highly selective BCR-ABL inhibitor for chronic myeloid leukemia (CML), which is designed to address primary resistance to allosteric inhibitors like SCEMBLIX.
- Early data for 001 showed 32% achievement of Major Molecular Response (MMR) in heavily pretreated late-line CML patients, including those resistant to asciminib.
- The company plans to initiate a Phase III study for 001 next year (2026), enrolling 400-500 patients in a second-line plus trial design.
- EnLiven ended the last quarter with approximately $480 million in cash, providing a runway into the first half of 2029, which is expected to cover the top-line data for the pivotal trial.
Nov 18, 2025, 4:00 PM
Enliven Provides Update on CML Program 001 and Financial Runway
ELVN
New Projects/Investments
Guidance Update
- Enliven (ELVN) is developing 001, an ATP-competitive BCR-ABL inhibitor for chronic myeloid leukemia (CML), with early data showing 32% achievement of MMR in heavily pretreated late-line patients.
- The company plans to initiate a Phase 3 study for 001 in 2026, enrolling 400-500 patients in a second-line plus trial design.
- Enliven's financial runway extends into the first half of 2029, with approximately $480 million in cash as of the last quarter.
- The company is also exploring combination studies and expects to disclose new non-oncology assets in 2026.
Nov 18, 2025, 4:00 PM
Enliven Therapeutics Details Phase 3 Plans and Financial Runway for CML Drug 001
ELVN
New Projects/Investments
Guidance Update
- Enliven Therapeutics (ELVN) is developing 001, an ATP-competitive, highly selective BCR-ABL inhibitor for the treatment of patients with chronic myeloid leukemia (CML).
- Early data for 001 showed 32% achievement of Major Molecular Response (MMR) in heavily pretreated late-line CML patients, including those previously treated with and resistant or refractory to asciminib (Semblix).
- The company plans to initiate a Phase 3 study in 2026 with a second-line plus trial design, aiming to enroll 400-500 patients for a head-to-head study.
- Enliven differentiates its mechanism from allosteric inhibitors like Semblix and TURN701, positioning 001 to address primary resistance to these drugs, and is interested in exploring combination therapies in the future.
- Enliven ended the last quarter with approximately $480 million in cash and projects a financial runway into the first half of 2029, which is expected to cover well through the top-line data for the pivotal trial.
Nov 18, 2025, 4:00 PM
Enliven Therapeutics Reports Q3 2025 Financial Results and Business Update
ELVN
Earnings
Guidance Update
New Projects/Investments
- Enliven Therapeutics reported a net loss of $20.1 million for the third quarter of 2025, compared to a net loss of $23.2 million for the third quarter of 2024.
- Research and development expenses for the third quarter of 2025 were $18.2 million, while general and administrative expenses were $6.9 million.
- As of September 30, 2025, the company had $477.6 million in cash, cash equivalents, and marketable securities, which is expected to provide a cash runway into the first half of 2029.
- The company completed enrollment of the randomized Phase 1b cohorts of the ENABLE trial for ELVN-001 in CML and remains on track to initiate a Phase 3 pivotal trial for ELVN-001 in 2026.
Nov 12, 2025, 9:10 PM
Enliven Therapeutics Reports Q3 2025 Financial Results and Provides Business Update
ELVN
Earnings
New Projects/Investments
Guidance Update
- Enliven Therapeutics reported a net loss of $20.1 million for the third quarter ended September 30, 2025, compared to a net loss of $23.2 million for the same period in 2024.
- As of September 30, 2025, the company held $477.6 million in cash, cash equivalents, and marketable securities, which is expected to provide a cash runway into the first half of 2029.
- The company completed enrollment of the randomized Phase 1b cohorts of the ENABLE trial for ELVN-001 and remains on track to initiate a Phase 3 pivotal trial in 2026.
Nov 12, 2025, 9:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more